PDCD1 and non-small cell lung carcinoma: Sato et al. observed that patients with advanced NSCLC treated with anti-PD-1 who had immune-mediated adverse effects had a higher objective response rate (63.6% vs. 7.4%, p < 0.01) and longer progression-free survival (HR 0.10; 95% CI 0.04–1.46; p = 0.13) compared to those who did not have immune-related adverse effects [49].